Patients at the Myeloma Center have access to the newest therapies for plasma cell disorders through enrollment onto clinical trials. New clinical trials are now under continuing enrollment under the care of your treating physician. The myeloma center has access to both pharmaceutical industry and physician investigator initiated clinical trials as part of a world-class clinical research program.
In addition to clinical research, Weill Cornell Medical College has an active basic science laboratory-based research program in myeloma where new targets for drug therapy and disease control can be discovered. Innovations in the laboratory can then be used in an active bench-to-clinic translational research context, this offering patients in need the latest in personalized drug therapies.
Myeloma is a cancer of a type of white blood cell called the plasma cell. It is the job of the plasma cell to produce immunoglobulins, proteins which serve in an integral role in immune system protection. An abnormal proliferation of one type (or clone) or plasma cell can lead to a spectrum of blood disorders including MGUS (monoclonal gammopathy of undetermined significance), multiple myeloma, amyloidosis, light chain deposition disease, amongst others.
The Myeloma Center is Teaming Up with the Leukemia & Lymphoma Society to Light the Night
We are proud to be supporting the 2016 Leukemia & Lymphoma Society (LLS) Light the Night Event! Because of the commitment of organizations like LLS to fund innovative research projects and connect patients with supportive services, we have made great progress in the fight against multiple myeloma. Learn more about our research and join our team!
Sophisticated Testing Approaches Better Equip Physicians to Identify Myeloma Risks
Dr. Adriana Rossi talks with Healio about how primary care physicians and kidney specialists are becoming better at detecting an abnormal protein in the blood that's closely linked with myeloma. See what she has to say about how this leads to decreased suffering through earlier detection and intervention.
Changing the Cancer Conversation
In the June issue of Delta Sky Magazine, Dr. Ruben Niesvizky weighs in on the latest progress in multiple myeloma treatment.